Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 380 employees. About 70% of the employees and projects are externally funded. Read more
The Institute has internationally strong research groups within cancer genetics, cancer immunology, cell and tumor biology, molecular oncology and radiation biology and a strong suite of core facilities. There is close collaboration between researchers at the Institute and clinicians and diagnosticians including surgeons, oncologists and pathologists. Several employees are affiliated at both the clinic and institute. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, is organizationally under the Division of Cancer Medicine (Division Radium Hospital) and is a key partner in the Comprehensive Cancer Center at Oslo University Hospital.
The institute also interacts closely with Inven2 (TTO for UiO/OUH and the Regional Health Authority), The RadForsk investment fund, and Oslo Cancer Cluster with numerous innovations being commercialized.
The Institute is engaged in both basic and translational cancer research involving experimental research on model organisms from various evolutionary levels as well as human material from all types of cells and tissues. The co-localisation with a large cancer hospital fulfils the premises for advanced medical research across sciences, a necessity towards the goals of individualised diagnostics and treatment for cancer patients.